Listed by the USPTO as CARCANAGUE, DANIEL R
Tech Center 1600 • Art Units: 1621 1625
This examiner grants 81% of resolved cases
Daniel R. Carcanague has overseen 930 resolved cases in Art Unit 1621, maintaining an allowance rate of 80.8 percent. The median pendency to reach an allowance is 616 days within Tech Center 1600. An interview lift of 24.5 percent is also recorded for these cases.
The 24.5 percent interview lift indicates that verbal advocacy is a productive tool for further improving the 80.8 percent allowance probability. Practitioners should consider this lift alongside the efficient 616-day median wait for an allowance. The 930 resolved cases provide a substantial data set for understanding prosecution in this unit.
Xenon Pharmaceuticals Inc. and Shionogi Pharma Co. Ltd. are the top companies appearing before this examiner. Firms such as COOLEY LLP and WENDEROTH, LIND & PONACK, L.L.P. have experience with these cases. The 80.8 percent allowance rate and 616-day median timeline define the environment for these 930 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18746981 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | Non-Final OA | Xenon Pharmaceuticals Inc. |
| 18196255 | NOVEL ACRIDINIUM SALT AND METHOD FOR PRODUCING SAME | Non-Final OA | SHIONOGI PHARMA CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy80.8% of resolved applications examined by Daniel R Carcanague were allowed (930 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +24.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Daniel R Carcanague took 616 days on average from filing to allowance.
Daniel R Carcanague examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
